| 摘要 |
The current therapeutic approach to treating patients with HIV-1 infection involves the use of one or more highly active antiretroviral therapeutics (HAART). While efficacious, this approach does not address the existance of latently infected cells. Such latently infected cells can be reactivated, resulting in the expression of infectious virus and reinitiation of the disease process. The present invention relates to a novel and highly efficacious approach to eradication of HIV-1. Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given to inhibit any residual viral replication. The therapeutic regimen is continued with the addition of compounds, such as OKT3 and IL-2, that activate latently infected cells, thereby stimulating the replication of any proviruses. These re-activated viruses are subsequently inhibited by the HAART and hydroxyurea/ddI therapeutics. Thus, the present invention provides a method of treating HIV-1 to eradicate any low-level viral replication and latently infected cells, thereby eliminating residual HIV-1 disease.
|
